|
Atrial Fibrillation
|
0.400 |
Biomarker
|
disease |
CTD_human |
Multi-ethnic genome-wide association study for atrial fibrillation.
|
29892015 |
2018 |
|
Atrial Fibrillation
|
0.400 |
GeneticVariation
|
disease |
GWASCAT |
Multi-ethnic genome-wide association study for atrial fibrillation.
|
29892015 |
2018 |
|
Atrial Fibrillation
|
0.400 |
GeneticVariation
|
disease |
GWASCAT |
Biobank-driven genomic discovery yields new insight into atrial fibrillation biology.
|
30061737 |
2018 |
|
Paroxysmal atrial fibrillation
|
0.300 |
Biomarker
|
disease |
CTD_human |
Multi-ethnic genome-wide association study for atrial fibrillation.
|
29892015 |
2018 |
|
Persistent atrial fibrillation
|
0.300 |
Biomarker
|
phenotype |
CTD_human |
Multi-ethnic genome-wide association study for atrial fibrillation.
|
29892015 |
2018 |
|
familial atrial fibrillation
|
0.300 |
Biomarker
|
phenotype |
CTD_human |
Multi-ethnic genome-wide association study for atrial fibrillation.
|
29892015 |
2018 |
|
Glioma
|
0.200 |
AlteredExpression
|
disease |
BEFREE |
Resveratrol can inhibit the growth and proliferation of glioma and promote its apoptosis through upregulating the LRIG1 gene expression, which plays the effect of antiglioma growth, revealing that LRIG1 is a new biological target of resveratrol in antiglioma cell proliferation and growth.
|
29745084 |
2019 |
|
Glioma
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
Thus, for the first time, changes in physiological Lrig1 expression have been linked to gliomagenesis, whereby the SNP rs11706832 may affect glioma risk by regulating LRIG1 expression.
|
29391393 |
2018 |
|
Glioma
|
0.200 |
GeneticVariation
|
disease |
GWASCAT |
Genome-wide association study of glioma subtypes identifies specific differences in genetic susceptibility to glioblastoma and non-glioblastoma tumors.
|
28346443 |
2017 |
|
Glioma
|
0.200 |
Biomarker
|
disease |
BEFREE |
MiR-20a mediated TMZ-resistance in glioblastoma cells through negatively regulating LRIG1 expression, which suggesting that miR-20a and LRIG1 would be potential therapeutic targets for glioma therapy.
|
25960225 |
2015 |
|
Glioma
|
0.200 |
AlteredExpression
|
disease |
BEFREE |
We constructed an enhanced green fluorescent protein plasmid (pEGFP) system, pEGFP-C1-LRIG1, for overexpression of LRIG1, and transfected it into human glioma cell line SHG-44.
|
25860915 |
2015 |
|
Glioma
|
0.200 |
AlteredExpression
|
disease |
BEFREE |
In addition, we showed that the expression level of LRIG1 was significantly negatively correlated with BCL-2 and MnSOD expression in glioma.
|
25449296 |
2015 |
|
Glioma
|
0.200 |
Biomarker
|
disease |
BEFREE |
The soluble LRIG1 ectodomain is demonstrated to be shed naturally and inhibit the progression of glioma.
|
25353163 |
2014 |
|
Glioma
|
0.200 |
AlteredExpression
|
disease |
BEFREE |
LRIG1 was negatively correlated with BCL-2 expression in glioma tissue and U251/MDR cells, and upregulation of LRIG1 can enhance chemosensitivity and inhibit BCL-2 expression.
|
25048475 |
2014 |
|
Glioma
|
0.200 |
Biomarker
|
disease |
BEFREE |
LRIG1 functions as a tumor suppressor in the pathogenesis of glioma via EGFR/Akt/c-Myc activation.
|
23124613 |
2013 |
|
Glioma
|
0.200 |
Biomarker
|
disease |
BEFREE |
Our findings suggest that LRIG1 restricted glioma aggressiveness by inhibiting cell proliferation, migration and invasion.
|
23337938 |
2013 |
|
Glioma
|
0.200 |
AlteredExpression
|
disease |
BEFREE |
These findings suggest that upregulation of LRIG1 expression enhances the CDDP sensitivity in the glioma cell line U251.
|
23581227 |
2012 |
|
Glioma
|
0.200 |
Biomarker
|
disease |
BEFREE |
These findings indicate that LRIG2 possesses distinct functions compared with LRIG1 and validate the attractiveness of LRIG2 as a target in glioma therapy.
|
19421009 |
2009 |
|
Glioma
|
0.200 |
AlteredExpression
|
disease |
BEFREE |
LRIG1-3 mRNA was detected in all human glioma cell lines and matched glioma samples, with large differences in the expression levels.
|
16532360 |
2006 |
|
Colorectal Carcinoma
|
0.140 |
GeneticVariation
|
disease |
GWASCAT |
Novel Common Genetic Susceptibility Loci for Colorectal Cancer.
|
29917119 |
2019 |
|
Colorectal Carcinoma
|
0.140 |
AlteredExpression
|
disease |
BEFREE |
Finally, in a cohort of xenopatients, stratified for response to cetuximab, we observed an inverse association between the expression level of LRIG1 and CRC progression upon CTX treatment.
|
31052457 |
2019 |
|
Colorectal Carcinoma
|
0.140 |
AlteredExpression
|
disease |
BEFREE |
LRIG1 is down-regulated in various epithelial cancers, including bladder, breast, and colorectal cancer, suggesting that it functions as a tumor suppressor.
|
30248341 |
2018 |
|
Colorectal Carcinoma
|
0.140 |
GeneticVariation
|
disease |
GWASCAT |
Genome-wide association study of colorectal cancer identifies six new susceptibility loci.
|
26151821 |
2015 |
|
Colorectal Carcinoma
|
0.140 |
PosttranslationalModification
|
disease |
BEFREE |
A significant increase in LRIG1 methylation was identified in CRC specimens compared to adjacent normal tissues and that it was negatively correlated with its mRNA and protein expression.
|
26159916 |
2015 |
|
Colorectal Carcinoma
|
0.140 |
AlteredExpression
|
disease |
BEFREE |
In conclusion, there was a great heterogeneity in the expression of the LRIG1 protein in colorectal cancer, which was not related to gene dosage of the LRIG1 gene.
|
17851870 |
2007 |